Medpace Holdings, Inc. $MEDP Shares Sold by CX Institutional

CX Institutional cut its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 31.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,962 shares of the company’s stock after selling 1,390 shares during the quarter. CX Institutional’s holdings in Medpace were worth $1,569,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of MEDP. AQR Capital Management LLC raised its holdings in Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after acquiring an additional 324,293 shares during the last quarter. Wasatch Advisors LP grew its position in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the period. Geode Capital Management LLC increased its stake in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Invesco Ltd. lifted its position in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after buying an additional 38,760 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on MEDP shares. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and raised their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Mizuho upped their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Robert W. Baird increased their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Finally, Truist Financial boosted their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Two analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $584.18.

Medpace Stock Up 2.2%

MEDP opened at $587.75 on Thursday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The company has a 50 day moving average of $516.53 and a two-hundred day moving average of $492.28. The company has a market cap of $16.40 billion, a P/E ratio of 34.45, a P/E/G ratio of 2.57 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insider Buying and Selling at Medpace

In related news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 3,728 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $600.85, for a total value of $2,239,968.80. Following the completion of the transaction, the chief executive officer owned 642,456 shares of the company’s stock, valued at approximately $386,019,687.60. This represents a 0.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 31,087 shares of company stock valued at $16,203,054 over the last three months. 20.50% of the stock is owned by company insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.